BRAF and melanoma: In fact, outcomes of clinical trials performed over the last few years demonstrated that adjuvant therapies with ipilimumab, nivolumab, pembrolizumab, dabrafenib, and trametinib in patients with BRAF-mutated melanoma positively affect the overall survival (OS) and/or the relapse-free survival of patients [67,68,69,70,71,72].